An interventional study of Active tDCS and Sham tDCS in Acute Lymphoblastic Leukemia, sponsored by St. Jude Children's Research Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by St. Jude Children's Research Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital — 15 open to participants now, 25 under way, 1 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · St. Jude Children's Research Hospital.
Among the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital, this one is the 11th largest by enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2019, is one of 12 with no phase, and was the 49th registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →15 of the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital are open now, in 1 country. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
St. Jude Children's Research Hospital · Sites in United States
Ages 8+ · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
St. Jude Children's Research Hospital · Sites in United States
Ages 18+
St. Jude Children's Research Hospital · Sites in United States
Ages 20–50
By country, each count listing its studies:
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 39 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 24 · Phase 3 8 · Phase 4 2
First in 1993; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is above the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 42 across the 57 interventional studies, 165 across the 13 observational. Of the 44 that completed or were terminated, 17 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
6 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747910St. Jude Children's Research HospitalAssessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma | 2026-12 |
| NCT04195347St. Jude Children's Research HospitalStudy of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase | 2027-01 |
| NCT05763290St. Jude Children's Research HospitalChildhood Cancer Survivors' Affective Response to Exercise | 2027-02 |
| NCT06819475St. Jude Children's Research HospitalImaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors | 2027-07 |
| NCT04881240St. Jude Children's Research HospitalStudy of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia | 2027-07-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Long-term survivors of ALL are at-risk for neurocognitive impairment, particularly in the area of executive functioning. Relatively limited research has focused on interventions for improving neurocognitive outcomes in long-term survivors of ALL. A promising technique for cognitive enhancement is Transcranial Direct Current Stimulation (tDCS) which differs from conventional cognitive remediation approaches in that it directly stimulates specific brain regions responsible for cognitive processes and activates functional networks similar to those activated during cognitive training.
Primary Objective
To evaluate the efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on direct testing of executive function in survivors of ALL.
Secondary Objectives
Eligible participants will be randomized to receive 1 mA direct current stimulation over the left dorsolateral prefrontal cortex or placebo/sham for 20 minutes. All participants will receive home-based computerized cognitive training. Participants will complete tDCS paired with cognitive training 2 times per week for 6-months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Remotely delivered active tDCS + cognitive training
Device: Active tDCS
Remotely delivered sham tDCS + cognitive training
Device: Sham tDCS
Participants will receive active 1mA direct current stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
Participants will receive sham (no direct current) stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
Direct Testing of Executive Function: Change in Working Memory From Baseline to 6 Months
Efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on neurocognitive functioning in long- term survivors of ALL. The measures were analyzed to compare changes in neurocognitive performance from baseline to 6 months between active treatment and placebo groups. The unit of measure is a standardized z-score with a mean of 0 and a standard deviation of 1. A higher z-score represents a better outcome. Digit Span Backward: Digit Span Backward (DSB), from the Digit Span subtest on the WAIS-IV, is a measure of working memory. The number of digits recalled in the longest span is converted to a standard z-score using age-based norms (Mean=0, SD=1). A higher z-score represents a better outcome.
Time frame: Baseline & 6-month follow-up
Direct Testing of Executive Function: Change in Cognitive Flexibility in Baseline to 6 Months
Efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on neurocognitive functioning in long- term survivors of ALL. The measures were analyzed to compare changes in neurocognitive performance from baseline to 6 months between active treatment and placebo groups. The unit of measure is a standardized z-score with a mean of 0 and a standard deviation of 1. A higher z-score represents a better outcome. Trail Making Test Part B (Trails B): This is a timed task that requires a participant to shift his/her attention adaptively and flexibly. Age-based standardized z-scores are calculated (Mean=0, SD=1). A higher z-score represents a better outcome.
Time frame: Baseline & 6-month follow-up
Direct Testing of Executive Function: Change in Verbal Fluency From Baseline to 6 Months
Efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on neurocognitive functioning in long- term survivors of ALL. The measures were analyzed to compare changes in neurocognitive performance from baseline to 6 months between active treatment and placebo groups. The unit of measure is a standardized z-score with a mean of 0 and a standard deviation of 1. A higher z-score represents a better outcome. Controlled Oral Word Association (COWA): This is a task of cognitive/verbal fluency that measures spontaneous production of words beginning with a designated letter or category. Age-based standardized z-scores are calculated (Mean=0, SD=1). A higher z-score represents a better outcome.
Time frame: Baseline & 6-month follow-up
Change in Patient-Reported Symptoms of Executive Functioning From Baseline to 6 Months
Patient reported symptoms of executive dysfunction will be evaluated via the Childhood Cancer Survivor Study Neurocognitive Questionnaire (CCSS-NCQ). The CCSS-NCQ is a 32-item questionnaire evaluating 4 domains of executive function. Z-scores (M=0, SD=1) are calculated using sibling data from the Childhood Cancer Survivor Study. Z-scores apply to all outcome rows (task efficiency, memory, organization, emotion regulation). A higher z-scores represents a better outcome.
Time frame: Baseline and 6-month follow-up
Change in Patient-Reported Symptoms of Executive Functioning From Baseline to 6 Months
Patient reported symptoms of executive dysfunction will be evaluated via the Behavior Rating Inventory for Executive Function - Adult Version (BRIEF-A). The BRIEF-A is a 75-item measure of executive function that provides age- and sex-specific national normative data for nine domains of executive function Z-scores (M=0, SD=1) are reported. A higher z-score represents a better outcome.
Time frame: Baseline and 6-month follow-up
Change in Structural Brain Connectivity From Baseline to 6 Months
Structural brain networks are constructed from pair-wise white matter connections between brain regions from diffusion tensor imaging. Streamline density is a normalized (values between 0 and 1), unitless measure that characterizes the amount of white matter connectivity between 2 regions of interest. Higher streamline densities suggest a stronger, more robust structural connection. Here, a positive or negative change in streamline density indicates strengthening or weakening connectivity, respectively.
Time frame: Baseline and 6-month follow-up
Change in Functional Brain Connectivity From Baseline to 6 Months
Functional brain networks are constructed from pair-wise correlation of activity in brain regions during resting state functional-MRI. Global efficiency, local efficiency, and clustering coefficient are normalized graph metrics (values between 0 and 1) that characterize brain networks and follow an inverted U-shape. Tendency towards either extreme is associated with disrupted cognitive function. Global and local efficiency are measures of parallel information transfer across the whole brain network and smaller subnetworks respectively. Lower values denote less capacity for parallel information transfer than higher values. Clustering coefficient quantifies the tendency of a network to segregate into neighborhoods. Higher values denote higher segregation.
Time frame: Baseline and 6-month follow-up
Parameter Estimate (Beta Weight) of Left DLPFC During an N-Back Task From Baseline to 6 Months
Functional magnetic resonance imaging (fMRI) was used to measure local hemodynamics in a pre-defined region of interest (ROI) in the left dorsolateral prefrontal cortex (Left DLPFC). Individual task-related brain activity was modeled using a General Linear Model (GLM). Reported values represent the group mean parameter estimate (beta weight) extracted from the Left DLPFC ROI for the 2-back (working memory) condition relative to the 0-back (baseline) condition of an N-back task. A higher parameter estimate indicates greater relative neural activation during the working memory condition.
Time frame: Baseline & 6-month follow-up
A total of 127 patients were enrolled on the study from December 2019 to June 2023. Of the 127, 13 withdrew prior to randomization. 114 were randomized.
| Milestone | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS |
|---|---|---|
| Started | 55 | 59 |
| Completed | 38 | 48 |
| Not completed | 17 | 11 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Physician decision | 14 | 9 |
Efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on neurocognitive functioning in long- term survivors of ALL. The measures were analyzed to compare changes in neurocognitive performance from baseline to 6 months between active treatment and placebo groups. The unit of measure is a standardized z-score with a mean of 0 and a standard deviation of 1. A higher z-score represents a better outcome. Digit Span Backward: Digit Span Backward (DSB), from the Digit Span subtest on the WAIS-IV, is a measure of working memory. The number of digits recalled in the longest span is converted to a standard z-score using age-based norms (Mean=0, SD=1). A higher z-score represents a better outcome.
| Z-score | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS |
|---|---|---|
| Direct Testing of Executive Function: Change in Working Memory From Baseline to 6 Months | 0.23 ± 0.65 | 0.31 ± 0.79 |
Efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on neurocognitive functioning in long- term survivors of ALL. The measures were analyzed to compare changes in neurocognitive performance from baseline to 6 months between active treatment and placebo groups. The unit of measure is a standardized z-score with a mean of 0 and a standard deviation of 1. A higher z-score represents a better outcome. Trail Making Test Part B (Trails B): This is a timed task that requires a participant to shift his/her attention adaptively and flexibly. Age-based standardized z-scores are calculated (Mean=0, SD=1). A higher z-score represents a better outcome.
| Z-score | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS |
|---|---|---|
| Direct Testing of Executive Function: Change in Cognitive Flexibility in Baseline to 6 Months | 0.98 ± 1.264 | 0.74 ± 0.96 |
Efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on neurocognitive functioning in long- term survivors of ALL. The measures were analyzed to compare changes in neurocognitive performance from baseline to 6 months between active treatment and placebo groups. The unit of measure is a standardized z-score with a mean of 0 and a standard deviation of 1. A higher z-score represents a better outcome. Controlled Oral Word Association (COWA): This is a task of cognitive/verbal fluency that measures spontaneous production of words beginning with a designated letter or category. Age-based standardized z-scores are calculated (Mean=0, SD=1). A higher z-score represents a better outcome.
| Z-score | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS |
|---|---|---|
| Direct Testing of Executive Function: Change in Verbal Fluency From Baseline to 6 Months | 0.25 ± 0.54 | 0.19 ± 0.77 |
Patient reported symptoms of executive dysfunction will be evaluated via the Childhood Cancer Survivor Study Neurocognitive Questionnaire (CCSS-NCQ). The CCSS-NCQ is a 32-item questionnaire evaluating 4 domains of executive function. Z-scores (M=0, SD=1) are calculated using sibling data from the Childhood Cancer Survivor Study. Z-scores apply to all outcome rows (task efficiency, memory, organization, emotion regulation). A higher z-scores represents a better outcome.
| Z-score | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS |
|---|---|---|
| NCQ - Task Efficiency | -0.11 ± 1.02 | 0.01 ± 1.05 |
| NCQ - Memory | 0.17 ± 1.28 | 0.09 ± 1.19 |
| NCQ - Organization | 0.01 ± 0.63 | -0.26 ± 1.09 |
| NCQ - Emotion Regulation | 0.18 ± 0.89 | 0.05 ± 0.87 |
Patient reported symptoms of executive dysfunction will be evaluated via the Behavior Rating Inventory for Executive Function - Adult Version (BRIEF-A). The BRIEF-A is a 75-item measure of executive function that provides age- and sex-specific national normative data for nine domains of executive function Z-scores (M=0, SD=1) are reported. A higher z-score represents a better outcome.
| Z-score | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS |
|---|---|---|
| Global Executive Composite | -0.34 ± 0.68 | -0.27 ± 0.86 |
| Inhibition | -0.38 ± 0.62 | -0.14 ± 0.90 |
| Self-Monitoring | -0.17 ± 0.63 | -0.08 ± 0.87 |
| Shift | -0.31 ± 0.87 | -0.21 ± 0.92 |
| Emotional Control | -0.18 ± 0.71 | -0.17 ± 0.86 |
| Initiation | -0.34 ± 0.84 | -0.24 ± 1.01 |
| Working Memory | -0.25 ± 0.81 | -0.50 ± 1.08 |
| Planning | -0.31 ± 0.89 | -0.09 ± 0.83 |
| Task Monitoring | -0.26 ± 0.70 | -0.27 ± 0.89 |
| Organization of Materials | -0.25 ± 0.57 | -0.16 ± 0.87 |
| Behavior Regulation Index | -0.30 ± 0.64 | -0.18 ± 0.89 |
| Metacognition Index | -0.32 ± 0.73 | -0.28 ± 0.86 |
Structural brain networks are constructed from pair-wise white matter connections between brain regions from diffusion tensor imaging. Streamline density is a normalized (values between 0 and 1), unitless measure that characterizes the amount of white matter connectivity between 2 regions of interest. Higher streamline densities suggest a stronger, more robust structural connection. Here, a positive or negative change in streamline density indicates strengthening or weakening connectivity, respectively.
| Normalized streamline density | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS |
|---|---|---|
| Difference in Frontostriatal Connections (Left) | 0.1161 ± 0.3603 | -0.1410 ± 0.3483 |
| Difference in Frontostriatal Connections (Right | 0.0828 ± 0.4248 | -0.0295 ± 0.2849 |
Functional brain networks are constructed from pair-wise correlation of activity in brain regions during resting state functional-MRI. Global efficiency, local efficiency, and clustering coefficient are normalized graph metrics (values between 0 and 1) that characterize brain networks and follow an inverted U-shape. Tendency towards either extreme is associated with disrupted cognitive function. Global and local efficiency are measures of parallel information transfer across the whole brain network and smaller subnetworks respectively. Lower values denote less capacity for parallel information transfer than higher values. Clustering coefficient quantifies the tendency of a network to segregate into neighborhoods. Higher values denote higher segregation.
| Normalized metric (range: 0-1) | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS |
|---|---|---|
| Global Efficiency change | 0.0043 ± 0.0107 | 0.0039 ± 0.0107 |
| Local Efficiency chnage | -0.0060 ± 0.0220 | -0.0109 ± 0.0222 |
| Clustering Coefficient change | -0.0105 ± 0.0447 | -0.0188 ± 0.0545 |
Functional magnetic resonance imaging (fMRI) was used to measure local hemodynamics in a pre-defined region of interest (ROI) in the left dorsolateral prefrontal cortex (Left DLPFC). Individual task-related brain activity was modeled using a General Linear Model (GLM). Reported values represent the group mean parameter estimate (beta weight) extracted from the Left DLPFC ROI for the 2-back (working memory) condition relative to the 0-back (baseline) condition of an N-back task. A higher parameter estimate indicates greater relative neural activation during the working memory condition.
| beta weight | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS |
|---|---|---|
| Left DLPFC at baseline | .6772 ± .3486 | .5634 ± .4124 |
| Left DLPFC at follow-up | 0.6340 ± 0.4446 | .7727 ± 0.3941 |
Collected over Adverse events were surveyed weekly, with symptoms reported for the two prior weekly stimulation sessions. starting at baseline (study enrollment) up to 24 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Comparator: Sham tDCS | 1/38 (2.6%) | 1/38 (2.6%) | 37/38 (97.4%) |
| Active Comparator: Active tDCS | 1/48 (2.1%) | 1/48 (2.1%) | 47/48 (97.9%) |
| Event | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS |
|---|---|---|
| AnxietyPsychiatric disorders | 1/38 | 0/48 |
| PainGeneral disorders | 0/38 | 1/48 |
| InfectionInfections and infestations | 0/38 | 1/48 |
| Event | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS |
|---|---|---|
| HeadacheNervous system disorders | 22/38 | 33/48 |
| Difficulty sleepingGeneral disorders | 19/38 | 26/48 |
| FatigueGeneral disorders | 16/38 | 19/48 |
| Drowsiness during the dayGeneral disorders | 14/38 | 20/48 |
| Poor concentrationPsychiatric disorders | 15/38 | 18/48 |
| Dry skinSkin and subcutaneous tissue disorders | 11/38 | 18/48 |
| PainGeneral disorders | 9/38 | 15/48 |
| ItchingSkin and subcutaneous tissue disorders | 9/38 | 14/48 |
| Sleeping too muchGeneral disorders | 9/38 | 14/48 |
| AnxietyPsychiatric disorders | 8/38 | 13/48 |
| Age, Continuous(years) | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS | Total |
|---|---|---|---|
| Mean | 32.72 ± 5.57 | 32.33 ± 6.06 | 32.50 ± 5.82 |
| Sex: Female, Male(Participants) | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS | Total |
|---|---|---|---|
| Female | 19 | 24 | 43 |
| Male | 19 | 24 | 43 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 8 | 11 |
| Not Hispanic or Latino | 35 | 40 | 75 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo Comparator: Sham tDCS | Active Comparator: Active tDCS | Total |
|---|---|---|---|
| Race — Black or African American | 6 | 5 | 11 |
| Race — White | 31 | 40 | 71 |
| Race — Other | 1 | 3 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2019 to primary completion in Jun 2023, 42 months.
Results were first posted in Oct 2026, 3 years 3 months after primary completion.
Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's 42 months is above that.
Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
St. Jude Children's Research Hospital →